Healthcare provider profile · identity verified

Sudeshna Mitra, MD

Allopathic & Osteopathic Physicians|Internal Medicine · MELBOURNE, FL · NPI 1831153469

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Sudeshna Mitra, MD received $123.00 in general payments during 2025 across 4 reported records.

Phathom Pharmaceuticals, Inc. accounted for 50.7% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.

Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$123.00

4 reported records · 4 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Phathom Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$62.36	50.7%	1	2025
Exact Sciences Corporation	Unresolved — no canonical attribution shown	$27.53	22.4%	1	2025
Boehringer Ingelheim Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$19.51	15.9%	1	2025
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$13.60	11.1%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$123.00	4

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
VOQUEZNA Normalized: voquezna	Drug	Phathom Pharmaceuticals, Inc.	$62.36	1	2025
Source payment records 2025-04-30 · Phathom Pharmaceuticals, Inc. · $62.36 · Open Payments source
The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit	Device	Exact Sciences Corporation	$27.53	1	2025
Source payment records 2025-09-25 · Exact Sciences Corporation · $27.53 · Open Payments source
Ozempic Normalized: ozempic	Drug	Novo Nordisk Inc	$13.60	1	2025
Source payment records 2025-06-03 · Novo Nordisk Inc · $13.60 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
Ozempic ozempic	2025	Ozempic	2024	83	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583	Jardiance · 2024 Exact normalized brand match · 1 Part D row	89	27
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	83	21
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Rybelsus open payments reported associated product	CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076	Rybelsus · 2024 Exact normalized brand match · 1 Part D row	23	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	530	168
Levothyroxine Sodium	Levothyroxine Sodium	475	134
Atorvastatin Calcium	Atorvastatin Calcium	363	110
Amlodipine Besylate	Amlodipine Besylate	314	103
Metoprolol Succinate	Metoprolol Succinate	248	69
Lisinopril	Lisinopril	231	82
Ibandronate Sodium	Ibandronate Sodium	180	63
Pantoprazole Sodium	Pantoprazole Sodium	172	67
Omeprazole	Omeprazole	162	52
Fluticasone Propionate	Fluticasone Propionate	158	80
Potassium Chloride	Potassium Chloride	157	46
Azithromycin	Azithromycin	151	127
Ezetimibe	Ezetimibe	151	51
Duloxetine Hcl	Duloxetine Hcl	147	44
Losartan Potassium	Losartan Potassium	142	41
Metformin Hcl	Metformin Hcl	142	50
Escitalopram Oxalate	Escitalopram Oxalate	137	49
Meloxicam	Meloxicam	136	65
Gabapentin	Gabapentin	134	44
Montelukast Sodium	Montelukast Sodium	130	39
Famotidine	Famotidine	124	48
Pravastatin Sodium	Pravastatin Sodium	121	34
Trazodone Hcl	Trazodone Hcl	116	40
Furosemide	Furosemide	113	40
Metoprolol Tartrate	Metoprolol Tartrate	113	39
Simvastatin	Simvastatin	110	33
Methylprednisolone	Methylprednisolone	103	81
Methocarbamol	Methocarbamol	100	67
Diclofenac Sodium	Diclofenac Sodium	98	39
Olmesartan Medoxomil	Olmesartan Medoxomil	98	27
Synthroid	Levothyroxine Sodium	97	31
Vitamin D2	Ergocalciferol (Vitamin D2)	96	32
Glimepiride	Glimepiride	93	34
Jardiance	Empagliflozin	89	27
Eliquis	Apixaban	83	16
Ozempic	Semaglutide	83	21
Bupropion Xl	Bupropion Hcl	81	29
Allopurinol	Allopurinol	76	25
Hydrochlorothiazide	Hydrochlorothiazide	75	30
Albuterol Sulfate Hfa	Albuterol Sulfate	74	31
Atenolol	Atenolol	73	23
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	65	18
Cefuroxime	Cefuroxime Axetil	62	40
Hydralazine Hcl	Hydralazine Hcl	61	18
Tamsulosin Hcl	Tamsulosin Hcl	57	13
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	55	46
Meclizine Hcl	Meclizine Hcl	55	25
Ciprofloxacin Hcl	Ciprofloxacin Hcl	53	42
Sertraline Hcl	Sertraline Hcl	53	16
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	53	44
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	47	17
Clopidogrel	Clopidogrel Bisulfate	44	13
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	44	12
Buspirone Hcl	Buspirone Hcl	43	16
Doxycycline Monohydrate	Doxycycline Monohydrate	42	37
Xarelto	Rivaroxaban	42	11
Carvedilol	Carvedilol	40	12
Farxiga	Dapagliflozin Propanediol	40	16
Lactulose	Lactulose	37	15
Fenofibrate	Fenofibrate	36	suppressed
Citalopram Hbr	Citalopram Hydrobromide	35	14
Propranolol Hcl	Propranolol Hcl	35	11
Lovastatin	Lovastatin	33	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	32	11
Warfarin Sodium	Warfarin Sodium	32	suppressed
Cholestyramine	Cholestyramine (With Sugar)	31	17
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	31	14
Rizatriptan	Rizatriptan Benzoate	30	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	30	suppressed
Finasteride	Finasteride	29	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	29	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	29	suppressed
Promethazine Hcl	Promethazine Hcl	29	16
Metformin Hcl Er	Metformin Hcl	28	11
Nifedipine Er	Nifedipine	28	suppressed
Alendronate Sodium	Alendronate Sodium	27	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	27	suppressed
Paroxetine Hcl	Paroxetine Hcl	27	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	26	11
Januvia	Sitagliptin Phosphate	26	suppressed
Mirtazapine	Mirtazapine	26	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	26	20
Spironolactone	Spironolactone	26	suppressed
Glipizide	Glipizide	25	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	25	25
Tradjenta	Linagliptin	25	suppressed
Fluconazole	Fluconazole	24	19
Nortriptyline Hcl	Nortriptyline Hcl	24	suppressed
Trulicity	Dulaglutide	24	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	23	22
Rybelsus	Semaglutide	23	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	23	15
Valacyclovir	Valacyclovir Hcl	23	13
Bumetanide	Bumetanide	22	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	22	suppressed
Ketoconazole	Ketoconazole	22	14
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Bupropion Hcl Sr	Bupropion Hcl	21	suppressed
Topiramate	Topiramate	21	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	20	suppressed
Levofloxacin	Levofloxacin	20	16
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	20	suppressed
Raloxifene Hcl	Raloxifene Hcl	20	suppressed
Ropinirole Hcl	Ropinirole Hcl	20	suppressed
Amoxicillin	Amoxicillin	19	18
Glyxambi	Empagliflozin/Linagliptin	19	suppressed
Ipratropium Bromide	Ipratropium Bromide	19	13
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	18	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	18	suppressed
Icosapent Ethyl	Icosapent Ethyl	18	suppressed
Tizanidine Hcl	Tizanidine Hcl	18	suppressed
Bydureon Bcise	Exenatide Microspheres	17	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Enoxaparin Sodium	Enoxaparin Sodium	16	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	16	suppressed
Fenofibric Acid	Fenofibric Acid (Choline)	16	suppressed
Gemfibrozil	Gemfibrozil	16	suppressed
Glyburide	Glyburide	16	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	16	suppressed
Naproxen	Naproxen	16	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	16	13
Ondansetron Hcl	Ondansetron Hcl	16	14
Donepezil Hcl	Donepezil Hcl	15	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	15	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	14	suppressed
Febuxostat	Febuxostat	14	suppressed
Lubiprostone	Lubiprostone	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Clobetasol Propionate	Clobetasol Propionate	13	suppressed
Insulin Lispro Protamine Mix	Insulin Lispro Protamin/Lispro	13	suppressed
Nebivolol Hcl	Nebivolol Hcl	13	suppressed
Novolog Flexpen	Insulin Aspart	13	suppressed
Unifine Pentips	Pen Needle, Diabetic	13	suppressed
Baclofen	Baclofen	12	suppressed
Breo Ellipta	Fluticasone/Vilanterol	12	suppressed
Cephalexin	Cephalexin	12	suppressed
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	12	suppressed
Jantoven	Warfarin Sodium	12	suppressed
Linzess	Linaclotide	12	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Valsartan	Valsartan	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Mounjaro	Tirzepatide	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$123.00 · 4 records	Phathom Pharmaceuticals, Inc.	Ozempic, The Cologuard Plus Collection Kit, VOQUEZNA	3	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Ozempic play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error